Paclitaxel-based therapy no better than cisplatin and 5-FU for operable esophageal cancer

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷 / 1期
关键词：
D O I：
10.1038/ncponc0992
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：7 / 8
页数：1
相关论文
共 50 条
  • [1] Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer
    Roof, Kevin S.
    Coen, John
    Lynch, Thomas J.
    Wright, Cameron
    Fidias, Panos
    Willett, Christopher G.
    Choi, Noah C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (04): : 1120 - 1128
  • [2] Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer
    Kelsey, Chris R.
    Chino, Junzo P.
    Willett, Christopher G.
    Clough, Robert W.
    Hurwitz, Herbert I.
    Morse, Michael A.
    Bendell, Johanna C.
    D'Amico, Thomas A.
    Czito, Brian G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : 770 - 776
  • [3] Neo-adjuvant radiation, cisplatin, 5-FU +/- paclitaxel in locally advanced esophageal cancer.
    Roof, KS
    Coen, J
    Lynch, TJ
    Wright, CD
    Fidias, P
    Willett, CG
    Choi, NC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 324S - 324S
  • [4] Optimal primary prophylaxis for febrile neutropenia during docetaxel, cisplatin, and 5-FU therapy for esophageal cancer
    Kumanishi, Ryosuke
    Taniguchi, Hiroya
    Kato, Kyoko
    Nakazawa, Taiko
    Ogata, Takatsugu
    Matsubara, Yuki
    Kodama, Hiroyuki
    Nakata, Akinobu
    Honda, Kazunori
    Masuishi, Toshiki
    Narita, Yukiya
    Kadowaki, Shigenori
    Ando, Masashi
    Sugiyama, Keiji
    Yamada, Keisaku
    Ohnishi, Sachiyo
    Tanaka, Tsutomu
    Tajika, Masahiro
    Abe, Tetsuya
    Muro, Kei
    ANNALS OF ONCOLOGY, 2022, 33 : S530 - S530
  • [5] Phase II trial of docetaxel and cisplatin in 5-FU/cisplatin pretreated refractory esophageal cancer
    Shim, H.
    Bae, W.
    Hwang, J.
    Cho, S.
    Nam, T.
    Chung, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
    Steber, Cole
    Hughes, Ryan T.
    McTyre, Emory R.
    Soike, Michael
    Farris, Michael
    Levine, Beverly J.
    Pasche, Boris
    Levine, Edward
    Blackstock, Arthur W.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [7] Definitive chemoradiation in esophageal squamous-cell carcinoma: Carboplatin/paclitaxel versus cisplatin/5-FU
    Tavares, N.
    Ribeiro, M.
    Meireles, S.
    Almeida, D.
    Aguas, L.
    Costa, A.
    Fontes, P.
    Damasceno, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 12 - 12
  • [8] The efficacy and feasibility of weekly 5-FU and cisplatin based radical concurrent chemoradiation therapy(CRT) in patients with esophageal cancer.
    Jeong, Joon Won
    Yang, Ji Hyun
    Ro, Sang Mi
    Kim, In-Ho
    Roh, Sang Young
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [9] Freedom from Recurrence after Induction Cisplatin/5-FU/RT versus Carboplatin/paclitaxel/RT in Patients with Esophageal Cancer
    Thomay, A. A.
    Su, S.
    Freidant, A. J.
    Ruth, K. J.
    Astsaturov, I. A.
    Burtness, B.
    Denlinger, C. S.
    Dotan, E.
    Hall, M. J.
    Meyer, J. E.
    Shah, P. C.
    Cohen, S. J.
    Scott, W. J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S152 - S152
  • [10] PHASE-II STUDY OF CISPLATIN, 5-FU, AND ALLOPURINOL IN ADVANCED ESOPHAGEAL CANCER
    DEBESI, P
    SILENI, VC
    SALVAGNO, L
    TREMOLADA, C
    CARTEI, G
    FOSSER, V
    PACCAGNELLA, A
    PERACCHIA, A
    FIORENTINO, M
    CANCER TREATMENT REPORTS, 1986, 70 (07): : 909 - 910
12345